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Abstract. During the last two decades, data generated by Next Generation 
Sequencing Technologies have revolutionized our understanding of human 
biology and improved the study on how changes (variations) in the DNA are 
involved in the risk of suffering a certain disease. A huge amount of genomic 
data is publicly available and frequently used by the research community in 
order to extract meaningful and reliable gene-disease relationships. However, 
the management of this exponential growth of data has become a challenge for 
biologists. Under such a Big Data problem perspective, they are forced to delve 
into a lake of complex data spread in over thousand heterogeneous repositories, 
represented in multiple formats and with different levels of quality; but when 
data are used to solve a concrete problem only a small part of that “data lake” is 
really significant; this is what we call the “smart” data perspective. By using 
conceptual models and the principles of data quality management, adapted to 
the genomic domain, we propose a systematic approach called SILE method to 
move from a Big Data to a Smart Data perspective. The aim of this approach is 
to populate an Information System with genomic data which are accessible, 
informative and actionable enough to extract valuable knowledge. 
Keywords: Conceptual Modelling, Data Quality, Big Data, Smart Data, 
Genomics. 
1 Introduction 
During the last two decades, advances in research technologies such as Next Generation 
Sequencing (NGS) have allowed us to read (sequence) DNA in a faster and cheaper way. It was 
a challenge until the completion of the Human Genome Project in 2003 and nowadays is 
becoming a routine research tool. This has revolutionized our understanding of human biology 
and improved the study on how changes (variations) in the DNA are involved in the risk of 
suffering a certain disease [1]. 
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The vast majority of the information generated by biological research centers or 
biotechnological world-wide consortia are publicly available to be used by the community: over 
thousand repositories of open genomic data, which help biologists and clinicians to extract 
meaningful gene-disease associations, improving their ability to tackle complex diseases in a 
multidisciplinary and individualized way (precision medicine). However, genomic repositories 
have been commonly developed in an ad-hoc way, focused on addressing specific knowledge 
requirements, but not designed to share information among them. 
Consequently, these repositories lack the holistic conceptual view required by a field as 
complex as Genomics is, leading to inconsistencies, redundancies, dispersion concerning data 
about a specific topic, different representations of the same concept and thus a high variability in 
their quality. The identification of novel disease-causing genes is highly dependent on our ability 
to gather and join all the relevant puzzle pieces together, reducing the noise as much as possible, 
which has become a challenge for biologists. 
On the one hand, there is a vast amount of data ready to be explored, but, on the other hand, 
only part of them is valuable to be applied in clinical practice. Big Data essentially means all 
data, but data lakes by themselves are meaningless for biologists. In order to obtain true benefits, 
big genomic data needs to be turned into actionable small datasets, clearly focused on the 
purpose, insights and resulting outcomes that can be used in daily work: e.g. to understand the 
genomic nature of a particular disease. This is why they are also the “smart” data required to 
manage adequately the information in such a complex context as Genomics. The core of our 
work is to provide a systematic approach to handle the huge amount of open genomic data, in 
order to get a subset, whatever the size is, valuable for biologists and cross functional; this is 
what we mean by ‘from Big Data to Smart Data perspective’. 
Conventional Big Data processing can be adapted to the genomic domain in order to solve 
most of the problems related to heterogeneity, data cleaning and data integration. But it leaves an 
important problem unsolved: the lack of an ontological commitment to define ground biological 
concepts; for instance, changes in the DNA sequence have been traditionally named as 
“mutations”, but this term has become increasingly problematic because usage by scientists is 
not uniform and has developed a negative connotation [2]. Substantial discrepancies in the 
meaning and use of key biological terms constitute an issue of concern, because they guide the 
understanding and processing of genomic data. If this issue remains open, the link between Big 
Data and Smart Data cannot be efficiently established. 
On the other hand, data quality has not been given due attention even though analytics and 
outcomes are highly dependent on the quality of the data on which they are based. For instance, 
there are different types of genomic databases regarding their level of curation
1
: from redundant 
and non-curated data warehouses that store millions of genomic sequences, such as TrEMBL
2
, to 
highly accurate databases manually annotated and reviewed by experts in an specific field, for 
instance Swiss-Prot
3
. In such a critical context as Genomics applied to clinical practice is, this 
aspect becomes especially relevant. The use of data quality management principles helps to 
select the appropriate repositories and the most valuable data, in order to ensure the higher 
veracity of the results. 
In this article, we present a systematic approach to extract small valuable datasets from the Big 
Data lake of Genomics, facing ontological and data quality challenges. The aim is to identify 
relevant variations in genes which are related to the risk of suffering a certain disease, which will 
be used to populate a Genomic Information System (GeIS). Our proposal is based on two 
principles: 
 The use of conceptual models to provide sound and coherent structure to the integrated data. 
 The use of data quality principles to ensure that data are relevant and reliable enough for the 
task at hand. 
                                               
1 Curation is the revision and annotation of biological data by experts in a specific field. 
2 http://www.uniprot.org/statistics/TrEMBL 
3 http://www.uniprot.org/statistics/Swiss-Prot 
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This article is structured as follows: in Section 2, we introduce the state of the art. Then, in 
Section 3 we present the “from Big Data to Smart Data” perspective applied to the genomic 
domain. In Section 4, we show how the Conceptual Schema of the Human Genome (CSHG) is 
useful to provide the ontological ground required to understand the key concepts of the domain. 
In Section 5, we explain the principles of Data Quality (DQ) which help to ensure the reliability 
required to apply the results to the clinic practice. In Section 6, we present a practical example of 
how this approach can be applied: the SILE method, which acronym refers to the stages that 
make it up (Search, Identification, Load and Exploitation). Finally, we expose the conclusions 
and future work in Section 7. 
2 State of the Art 
Many of the underlying principles of Big Data have been explored by the research community 
for years in different domains. Nevertheless, theories and approaches for analyzing big genomic 
data are relatively recent [3], [4], [5]. NGS requires more and more sophisticated algorithms and 
high-performance parallel processing systems to analyze and extract knowledge from a huge 
amount of genomic and molecular data. In this context, emerging deep learning algorithms help 
biotechnology researchers to perform Big Data analysis [6]. But these technological 
requirements are expensive, time consuming and commonly out of reach of biologists and 
experts who use these data for clinical purposes. In this case, Big Data is useful only if they can 
do something with it in their everyday jobs. For many problems and questions, Smart Data itself 
is enough, by creating and integrating small data "packages" and partitioning problems in a way 
that works across people and organizations. 
Due to the complexity of Genomics, in this article we focus on a particular use of genomic 
data applied to clinical practice: the identification of DNA variations in genes which are related 
with the risk of suffering a certain disease. In this case, a huge amount of open data repositories 
is available and the number of public biological data sources cannot be precisely determined on 
account of their volatility. Online catalogs such as the ones provided by the Nucleic Acid 
Research Journal (NAR) [7] or the Human Genome Variation Society
4
 (HGVS), are useful to get 
some idea of the multitude of repositories which are publicly available. Furthermore, some 
repositories are created for a specific purpose or in the context of a particular research and they 
are not updated or maintained so, as time goes by, they are no longer accessible or useful. In 
Figure 1, an example of the evolution in the number or public repositories during the last 4 years 
is presented. Each data source has advantages and disadvantages, which must be considered 
thoroughly according to the task to be performed. This means we do not have to query all 
available data sources but those that are relevant, reducing the volume of data to manage.  
On the other hand, these data sources contain millions of records with different levels of 
quality due to the complexity of biological processes, the noisy nature of experimental data and 
the limitations of statistical analysis; besides, there is a bias due to the use of different 
sequencing technologies and sampling strategies. This is the reason why only part of this “data 
lake” is reliable enough to provide precise clinical diagnosis and treatments. 
The study of data quality began in the 1990s, but it was not until 2011 that ISO published the 
ISO 8000 data quality standard. Nowadays, over 20 countries participate in its development, but 
it is controversial and standards need to be as much mature and perfect as possible. At the same 
time, research about data quality in Big Data, and particularly in genomics has just started and 
there are not sound results yet. Despite these challenges, the need to improve quality of genomic 
data is a key not only to achieve competitive advantage through its analysis, but because decision 
making based on low genomic data quality may involve serious mistakes with important 
consequences when applied with clinical purposes. 
                                               
4 http://www.hgvs.org/content/databases-tools 
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Figure 1. Number of biological databases added and removed from the NAR catalog in the last 4 years 
Genomic databases differ not only in the scope of the information they represent, but also in 
the way the same information is modelled. This situation hinders the process of retrieval, 
annotation and integration of heterogeneous datasets. When the research community realized that 
this issue was becoming a remarkable problem, some solutions were proposed. To represent 
different biological domains, the first approach was to construct ontologies, with the aim of 
unifying knowledge and making it interoperable through consistent vocabularies. But these 
ontologies became essentially large terminological resources, used as a glossary of genomic 
terms that are too often heterogeneous, imprecise and even inconsistent when compared. 
Examples of such a well-known type of ontologies – Gene Ontology (GO) [8], [9], which defines 
concepts/classes used to describe gene functions and relationships between them; Sequence 
Ontology (SO) [10], which defines a set of terms and relationships to describe the features and 
attributes of biological sequences; and Variation Ontology (VariO) [11], which defines the 
effects, mechanisms and sequences of genomic variations. Each of these ontologies describes a 
specific part of the genomic domain, but when we look for a common conceptual schema in 
order to have a holistic view of all this knowledge, there is not a clear solution. 
Some databases such as dbSNP
5
 provide schemas for explaining the structure of the data they 
store, but they usually are very complex to understand. Additionally, they are focused on 
satisfying the needs they were created for and it was not considered the option of interoperating 
with other repositories. 
The idea of applying conceptual modelling to understand the genome has been explored by 
some authors. It was firstly introduced by Paton et al. in 2000 [12]. They proposed a set of data 
models to describe elements involved in transcriptional and translational processes, as well as the 
variant effects generated by them. Later on, Ram and Wei [13] have also applied conceptual 
modelling principles in the context of 3D protein structure, and Bernasconi et al. proposed a 
conceptual model for describing metadata of experiments [14]. In any case, these approaches still 
focus on specific parts of the domain and do not provide the required global view. 
In next section we introduce the “from Big Data to Smart Data” perspective applied to the 
genomic domain and how the CSHG and a Data Quality Methodology are the key to achieve it. 
                                               
5 https://www.ncbi.nlm.nih.gov/SNP/ 
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3 From Big Data to Smart Data Perspective 
The term “Smart Data” contrasts with the term “Big Data”, which usually refers to a 
combination of structured and unstructured data that may be measured in petabytes or exabytes. 
Smart Data, in contrast, consists of usable datasets derived from Big Data repositories. 
Volume, Velocity and Variety are the three Vs in the original deﬁnition of the key 
characteristics of Big Data according to the research report published by META Group [15]. 
Volume refers to the size of the data, Velocity refers to the speed of data generation and Variety 
refers to different types/sources of data. Since then, other factors have also been considered, such 
as Veracity (trustworthiness of the data obtained) and Value (usefulness of data) [16].  
As a huge research has been done in Big Data processing, usually focused on Volume, 
Velocity and Variety, we are going to focus on how can we reduce the noise and identify the 
most reliable data useful for clinical practice (Veracity and Value). The right path we propose to 
achieve this goal is to add conceptual modelling techniques and data quality management to the 
traditional Big Data Processing, as can be shown in Figure 2. 
 
Figure 2. From Big Data to Smart Data perspective 
Most databases gather information from different biological contexts such as Epigenomics, 
Proteomics or Pharmacogenomics. The researchers may link datasets to combine information 
from multiple sources, in order to increase the richness of the information available to answer a 
research task. But the lack of consensus when defining ground biological concepts can be a huge 
problem when integrating information from different repositories. The use of a conceptual model 
(CM), provides the ontological basis to unambiguously define each biological concept, needed to 
identify the data in the repository whatever the term used to represent it. This helps to provide 
structure to the heterogeneous data managed, as well as making easier the access to an integrated 
dataset that can be used in daily work. The conceptual model can be used as a solid ontology 
representation to address issues of semantic integration between different datasets. 
On the other hand, the use of databases with large amounts of missing information, or that do 
not have rigorous and standardized data editing, cleaning, and processing procedures, increases 
the risk of inconclusive and potentially invalid results. After all, the value of the results is only as 
good as the quality of the data used. According to this issue, one question arises: How can a 
database be considered as relevant for the task at hand? The use of data quality management 
techniques is helpful to determine the most suitable data sources, and its application will be 
explained in Section 5. 
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In conclusion, the systematic application of conceptual modelling and data quality criteria is a 
key to create the link between the Big Data perspective and the Smart Data perspective. It 
provides Veracity and Value to the final dataset that will be used in clinical practice, as can be 
shown in Figure 3. 
 
Figure 3. The 5 Vs of the Smart Data Perspective 
In the next section, we will introduce the Conceptual Schema of the Human Genome (CSHG), 
an essential component to provide structure to this complex domain and the starting point for 
identifying valuable genomic information. 
4 The Conceptual Schema of the Human Genome 
To achieve what we refer to as the “Smart Data” perspective presented in this article, we need a 
conceptual structure to store each piece of genomic data in the right place, regardless of the data 
origin. To accomplish this goal, we propose the use of the Conceptual Schema of the Human 
Genome (CSHG) [17], [18]. 
The CSHG has been developed under a close collaboration with experts in the domain. It is 
thus based on biological knowledge and independent of any specific data sources. This 
characteristic helps the experts in the domain to understand the structure of the information 
without the need of studying the internal schema of each repository. The CSHG has five main 
parts, each one related with a specific domain view [17]: 
 The Structural view, focused on describing the structure of the genome. 
 The Transcription view, focused on describing the components and concepts related with 
protein synthesis. 
 The Variation view, describing the changes in the sequence of reference. 
 The Pathway view, describing information about metabolic pathways. 
 The Bibliography and data bank view, focused on describing where the data comes from. 
In order to accomplish our task (specified in Section 2), we need to mine those databases 
which contain the data specified by the conceptual model about relationships between genes and 
diseases. To accomplish this task, we must focus on the variations in the DNA sequence and its 
clinical significance (pathogenic or benign), as well as the evidence that supports the assertion. 
As an example of use, if we focus on the Variation view of the CSHG, we can identify what a 
variation is and which its main components are (see Figure 4).  
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Figure 4. Representation of a DNA variation based on the CSHG 
According to the schema, a variation is a change in the DNA sequence which occurs in a 
certain position inside a chromosome and depending on its frequency and description it can be 
classified into different types (Mutant, Polymorphism, Single Nucleotide Polymorphism, Copy 
Number Variation, Insertion, Deletion, Indel and Inversion).  
The advantage of the CSHG over other options is that it covers the entire structure of the 
genome; so data stored in different genomic repositories can be easily connected by using this 
structure. The use of the CSHG allows the researchers to identify the relevant information 
needed to answer a knowledge requirement and thus, a notion of which type of data sources can 
provide it. 
The adaptability of conceptual models provides a flexible approach to extend them according 
to the evolution of the domain. As new discoveries are made, new concepts can be included in 
the schema, new relevant data sources can be easily considered and new attributes can be 
identified to improve the data analysis process. 
In the next section we will introduce how to use data quality principles to identify relevant 
repositories and reliable data from them. 
5 DQ Management Applied to Genomics 
Before one can address issues involved in analyzing and managing data quality in the genomic 
domain, it is important to well understand what data quality actually means. Data Quality (DQ) 
has been defined by Wang and Strong [19] as “fitness for use”, i.e. the ability of a data collection 
to meet users’ requirements. DQ is evaluated by means of different dimensions which definition 
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mainly depends on the context of use. A data quality dimension can be assessed by using specific 
metrics in order to get a quantitative measure that represents the quality of the data being 
managed. But to apply this knowledge properly a sound methodology needs to be defined. 
A DQ Methodology can be defined as “a set of guidelines and techniques that, starting from 
the input information concerning a given reality of interest, defines a rational process for using 
the information to measure and improve the quality of data of an organization through given 
phases and decision points” [20]. We propose to use a Data Quality Methodology specifically 
for the genomic domain in order to (i) ensure Veracity (selection of high quality repositories) and 
ii) provide Value (selection of high quality data from each repository). 
Using the CSHG as the conceptual core and the previously mentioned concepts of 
“dimension” and “metric”, the proposed DQ Methodology is divided into 5 phases: Dimension 
Description, Metric Description, Variable Selection, Minimum DQ Requirements and DQ 
Assessment (see Figure 5). 
 
Figure 5. Proposed Data Quality Methodology to ensure the veracity and value of the data 
The methodology must be based on a detailed description of the knowledge requirements to be 
solved. In next subsections, each phase of the methodology is going to be thoroughly explained. 
5.1 Phase I – Dimension Description 
The DQ literature provides an extensive classification of data quality dimensions. However, 
there are discrepancies in the definition of most of them due to the contextual nature of quality. 
The most important classifications of quality dimensions are provided by Wand and Wang [21], 
Wang and Strong [19], Redman [22] and Naumann [23]. Nevertheless, no general agreement 
exists either on which set of dimensions defines the quality of data, or on the exact meaning of 
each dimension. Thus, it is very important to make a detailed description of the dimensions that 
best fit our data quality requirements. 
Due to the specificity of the genomic domain, the first step to determine the interesting 
dimensions is to be able to understand the issues that affect the information. To accomplish this 
task, a study of the most common errors present in different well-known genomic data sources 
has been performed [24]. The study allowed us to classify them into nine major quality 
dimensions, which can be seen in Table 1. 
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Table 1. Name and description of the main quality dimensions determined 
Dimension Definition 
Accuracy Data corresponds to real-world values and is correct [36]. 
Completeness 
The extent to which data is not missing and all necessary values are 
represented [26]. 
Consistency 
Data must be consistent between systems and represented in the same format 
[19]. 
Redundancy 
The extent to which the information is redundant or the database contains 
duplicate records [20]. 
Currency The extent to which data is sufficiently up-to-date for the task at hand [22]. 
Believability The extent to which data is regarded as true and credible [26]. 
Relevancy Extent to which information is applicable and helpful for the task at hand [25]. 
Reputation 
The extent to which information is highly regarded in terms of source or 
content [27]. 
Accessibility 
Extent to which information is available, or easily and quickly retrievable 
[19]. 
The selection of relevant dimensions in a given scenario is mostly application-dependent. For 
instance, as Believability is a key dimension to determine quality of a genomic database, when 
measuring the quality of a specific variation for genomic diagnosis in a Precision Medicine 
context, we focus on Accuracy and Completeness. 
5.2 Phase II – Metric Description 
As mentioned before, a DQ metric is a quantitative indicator of an attribute or property that can 
be assessed to represent the quality of the data being measured. In general, multiple metrics can 
be associated with each data quality dimension. DQ metrics are mostly defined ad hoc to solve 
specific problems and thus, are dependent on the considered scenario. Some authors such as [25] 
have defined methodologies to establish general principles in order to guide the definition of data 
quality metrics in a proper way. 
The same dimension can be used to assess quality in more than one scenario and is 
distinguished by the metrics defined on each case. As an example applied to our work, 
Believability can be measured by two different metrics depending on the context: 
 Believability of a database: a metric to measure this dimension could be that the database 
must be supported by well-known institutions and its content is reviewed by experts. 
 Believability of a variation: a metric to measure this dimension could be that there must be at 
least one publication with credible statistics that supports the association between the 
variation and the studied disease. 
For each dimension identified in the previous phase, at least one metric must be adequately 
defined in order to measure the global data quality. 
5.3 Phase III – Variable Selection 
The task to be performed must drive the choice of the particular pieces of information (variables) 
which are critical to answer it. The description of the variables required is determined by the 
CSHG; and the specification of which ones are going to be used in the DQ assessment process is 
determined by the selected dimensions and their corresponding metrics. For instance, to measure 
the Believability of a variation we must focus on the number of publications related with it. 
According to the CSHG the most suitable attribute to measure this metric is “pubmed_id”, 
which is a unique identifier provided by the bibliographic repository PubMed to each publication 
it stores. If the variation has at least one PubMed id, then it passes the quality filter. 
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5.4 Phase IV – Minimum DQ Requirements 
The aim of this phase is to specifically determine the minimum levels of quality that the selected 
variables must fulfil according to the metrics specified in Phase II. Concrete acceptance criteria 
must be assigned to each metric, e.g. the number of different submitters providing information 
about a gene-disease association must be at least two. 
One of the biggest concerns in any investigation is missing data (Completeness) because they 
can compromise the validity of the resource and any conclusions obtained by using that 
information. It is important to determine which variables are more or less likely to be missing, to 
define a priori an acceptable percent of missing data, and to be aware of the effort that would 
have to be taken to minimize the amount of missing information.  
In Table 2, the attributes of the CSHG have been categorized as “Required” if the values must 
be present, “Recommended” if the values can be missing but they provide interesting 
information about the variation, and “Other” if the values can be missing. 
Table 2. Classification of the attributes of the CSHG according to completeness requirements 
Class Required Recommended Other 
Species assembly scientific_name 
common_name 
ncbi_taxon_id 
date_assembly 
source 
Chromosome nc_identifier  name 
sequence 
Chromosome 
element 
chromosome_element_id 
specialization type = "gene" 
start_position 
end_position 
strand 
 
Gene id_symbol official_name 
biotype 
gene_synonym 
start_gene_ng 
end_gene_ng 
id_hugo 
description 
status 
gc_percentage 
Variation db_variation_id 
clinically_important 
 description 
other_identifiers 
associated_genes 
omim 
creation_version 
Precise position   
Indel   ins_sequence 
ins_repetition 
del_bases 
SNP   map_weight 
SNP Allele allele   
SNP Allele Pop frequency   
Population name size description 
population_id 
SNP Genotype name   
Certainty level of certainty   
Bibliography db name_db  url 
Bibliography 
reference 
bibliography_reference_id title 
date pub 
abstract 
publication 
authors 
5.5 Phase V – DQ Assessment 
Once dimensions, metrics and minimum requirements are established a sound data quality 
assessment can be made over the databases and the information they store. The comparison of 
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the collected information and the minimum acceptance criteria provide the required dataset of 
high-quality which comes from the most adequate data sources and guide the decision making 
process. As an example, in Table 3 a summary of the steps followed to assess the Believability of 
a variation is shown. The example has been simplified, according to the steps previously 
explained, in order to ease its understanding. 
Table 3. Example of how to determine the believability of a variation 
Phase Description 
Phase I 
Dimension Description 
Believability: The extent to which data is regarded as true and credible. 
Phase II 
Metric Description 
Number of publications supporting the assertion. 
Phase III 
Variable Selection 
pubmed_id 
Phase IV 
Minimun DQ criteria 
pubmed_id > 0 
Phase V 
DQ Assessment 
Variations without publications associated to it will be excluded 
(pubmed_id <1) 
Finally, in the next section we are going to explain how the CSHG and the DQ Methodology 
proposed can be joined to accomplish our proposed “from Big Data to Smart Data perspective” 
for the genomic data management domain. 
6 From Big Data to Smart Data: The SILE Method 
In previous sections the need of the CSHG and the description of a DQ Methodology to 
determine relevant information has been described. But, how can be both proposals combined in 
order to move from the Big Data perspective to the Smart Data perspective? 
In this section we present our proposal to provide a systematic methodological approach in 
order to answer this question for the genomic domain. It is the so called Search-Identification-
Load-Exploitation (SILE) method. Its main goal is to systematize the search and identification of 
genomic information to be loaded, analyzed and exploited by a Genomic Information System 
(GeIS) based on the Conceptual Schema of the Human Genome (CSHG). A summary of the 
activities taking place on each level of the method is defined in Table 4. 
Table 4. Description of each level of the SILE method 
Level Description 
(S) Search 
Determination of the information context, required to solve a concrete 
need, as well as the selection of data sources to extract information from. 
(I) Identification 
Determination of a reliable and relevant dataset to be used to populate a 
database which structure is delimited by the CSHG. 
(L) Load Population of the database with the data identified in the previous level. 
(E) Exploitation 
Extraction of knowledge from the database by using tools to analyse and 
interpret genomic data. 
The proposal has been validated by populating the GeIS with relevant variations related with 
the risk of suffering the Early Onset type of Alzheimer’s Disease, and ready to be used by 
researchers in their clinical practice. 
Alzheimer’s Disease (AD) is a type of dementia, so it mainly affects to the capabilities and 
functionalities of the brain, decreasing them and hindering the patient’s normal life development. 
The Early-onset type (EOAD) starts to show symptoms before 65 years old (normally around 50) 
so truthful and contrasted information of quality is essential to be used in the context of the 
clinical diagnosis. Due to AD is a degenerative neuronal disorder, stopping it at time is the key to 
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increase the quality of life of patients, which is only possible through specific studies of its 
genotype-phenotype relation. 
In the next subsections we present the main purpose and steps that are performed on each level 
of SILE, with the aim of determining the genetic causes of EOAD. 
6.1 Search 
The task previously determined dictates the type of data required; and the researcher must best 
match the data to the question; i.e. variations in the DNA sequence of genes related to the risk of 
suffering the Early Onset Alzheimer’s Disease (clinical significance). 
As has been explained previously, by using the CSHG the most important attributes 
corresponding to each required piece of knowledge can be identified (the data context). This 
helps to select the most suitable and complete data sources to query the required information. 
In order to accomplish the proposed task, the types of genomic data sources required are: 
databases of sequences (genes and chromosomes), databases with information about genotype-
phenotype relationships and databases that store scientific literature. 
Once the context is established, proper data sources to provide the required data must be 
selected among all the publicly available repositories. At this point, the previously defined DQ 
Methodology is useful to determine those with the higher quality according to our DQ 
requirements. 
First of all, a set of interesting data quality dimensions to be checked has been selected: 
Believability, Relevancy, Reputation, Currency and Accessibility. By using the NAR Catalog, 
we performed a research of the databases which belong to the type of genomic data sources 
considered as relevant and as a result 43 repositories have been analyzed: 7 databases of 
sequences, 6 databases about the human genome, 27 databases about human genes and diseases, 
and 3 databases about scientific literature. Finally, 7 of them have been selected as the most 
reliable to extract the required information. The metrics that are used to select the databases are 
listed below: 
 Believability Dimension:  
- M1: The information stored in the database must be manually curated or reviewed by 
experts. This type of databases has been proved to be less error-prone than those which 
use algorithms to annotate the information [28]. 
- M2: There are quality controls to ensure the correctness of the submitted information 
(e.g. submission forms, automated control of HGVS expressions, etc.). 
 Relevancy Dimension:  
- M3: The database contains enough information and is useful to determine the required 
data, according to the attributes determined by the CSHG. 
 Reputation Dimension:  
- M4: The database must be maintained or supported by international or well-known 
national research centers, institutions or associations. 
 Currency Dimension: 
- M5: The database must be active and frequently updated as well as provide enough 
information about it; e.g. the date of the last update and the database version. 
 Accessibility Dimension:  
- M6: The information must be public and freely accessible. 
- M7: The database must provide mechanisms to download the search results. 
- M8: It is highly recommended that the database provides ways to allow the 
programmatic access to the information stored. 
In Table 5, we have summarized the results of the analysis of the top 10 repositories in order 
to clarify how the selection of the final set of databases has been performed. The results have 
been sorted according to the number of filters passed. 
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Table 5. Data Quality Assessment of 10 biological data sources (N/A: Not Applicable) 
 
Believability Relevancy Reputation Currency Accessibility 
M1 M2 M3 M4 M5 M6 M7 M8 
ClinVar 
        
Ensembl 
        
dbSNP 
        
RefSeq 
        
NCBI-Gene 
        
PubMed N/A N/A 
      
AlzForum 
       
 
LitVar BETA version 
      
SNPedia   
    
 
 
AD&FTDMDB6 
   
 >1 year 
 
  
We have selected the first 7 databases, where 5 of them belong to the National Center for 
Biotechnology Information of the United States
7
 (NCBI). This center is part of a global 
consortium to share information about advances in science and health by providing access to 
biomedical and genomic information. Most of the databases supported by NCBI have public 
access. The information about the structure elements of the DNA sequences is retrieved from the 
NCBI Reference Sequence Database
8
 (RefSeq), an integrated and non-redundant set of reference 
sequences. These sequences belong to the reference genome (also known as reference assembly) 
which is a digital nucleic acid sequence database, assembled by scientists as a representative 
example of a species' set of genes. Specific information about Genes is retrieved from NCBI 
Gene
9
, a repository of integrated information from a wide range of species. The information 
about bibliography is retrieved from PubMed
10
, a repository which stores more than 28 million 
citations for biomedical literature. 
The information about variation-disease relationships comes from different resources, due to 
the fact that each database stores information about a certain type of variations or diseases. In our 
case we have selected two databases which belong to NCBI: i) ClinVar
11
, a public archive of 
reports of the relationships among different types of human variations and phenotypes, with 
supporting evidence; ii) dbSNP
12
, a public archive of short sequence variations, including single-
base nucleotide substitutions, small-scale multi-base deletions or insertions, and microsatellite 
repeats. Besides, two more well-known databases are used to extract information: (i) Ensembl
13
, 
a repository which provides comparative information about different species, and tools to 
support research in many different areas including gene-disease associations, – the database is 
supported by the European Molecular Biology Laboratory's and European Bioinformatics 
Institute (EMBI-EBI); and (ii) AlzForum
14
, a platform to disseminate the evolving knowledge 
around basic, translational, and clinical research in the field of Alzheimer’s Disease. 
                                               
6 Alzheimer Disease & Frontotemporal Dementia Mutation Database 
7 https://www.ncbi.nlm.nih.gov/ 
8 https://www.ncbi.nlm.nih.gov/refseq/ 
9 https://www.ncbi.nlm.nih.gov/gene/ 
10 https://www.ncbi.nlm.nih.gov/pubmed/ 
11 https://www.ncbi.nlm.nih.gov/clinvar/ 
12 https://www.ncbi.nlm.nih.gov/projects/SNP/ 
13 https://www.ensembl.org/index.html 
14 https://www.alzforum.org/ 
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All the selected databases fulfill the established DQ requirements. As can be shown in Figure 
6, each database provides information about a specific area of the CSHG. This helps to join all 
the information under a holistic view, required to have a better understanding of the disease. 
 
Figure 6. Distribution of the selected databases according to the CSHG and their area of knowledge 
Some of the reasons why the other databases were excluded are: inactivity of the repository 
(e.g. AD&FTDMDB), lack of revision from experts (SNPedia) or not enough data about the 
evidence that supports the relationship between the variation and the disease. LitVar is a special 
case, due to it is a useful database supported by NCBI, but it is under development and currently 
the available release is a BETA version. This affects the believability of the information 
provided. 
6.2 Identification 
The identification level is a process consisting of two parts: 
 Identification of the most relevant and accurate data from the genomic repositories selected 
in the Search level. 
 Determination of correspondences between the attributes of the genomic repositories and the 
attributes in the Human Genome Database (HGDB). The HGDB is the core of the GeIS and 
is based on the structure provided by the CSHG. 
The genomic repositories selected in the Search level store multitude of variations associated 
to Alzheimer, as well as a huge amount of metadata related with them. For instance, ClinVar 
stores 221 variations, Ensembl – 1,020 and AlzForum – 355. But not all of them are useful for 
clinical purposes. Their applicability depends on multiple variables such as the size and 
specificity of the population selected to perform the study, the strength of the evidence which 
supports the association with the disease or the techniques used to draw the conclusions. 
In order to select clinically relevant genes and variations, a new set of data quality dimensions 
has been defined: Accuracy, Completeness, Consistency, Believability and Relevancy. The 
metrics used to determine relevant variations are listed below. 
 Accuracy Dimension:  
- M1: Review attributes liable to be error-prone. Syntactic errors must be checked using 
controlled vocabularies and specific data dictionaries. 
 Completeness Dimension:  
- M2: The minimum information required to be stored in the HGDB is present. These 
attributes have been determined during Phase IV of the DQ Methodology. 
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 Consistency Dimension:  
- M3: The information about the variations is defined by using standard vocabularies and 
verified ontologies to determine critical attributes such as HGVS expressions, 
pathogenicity or functional effects. 
- M4: There must not be conflicts in the clinical interpretation of each variation. 
- M5: There must not be conflicts among databases related to the structural characteristics 
of the variation. 
 Believability Dimension:  
- M6: Each variation must have significant medical or genealogical consequences and be 
reproducible (e.g. the reported consequence has been independently replicated by at least 
one group besides the first group reporting the finding).  
- M7: The relationship between the variation and the disease must have at least a link to 
published, peer-reviewed paper with credible statistics and free access. 
 Relevancy Dimension: 
- M8: The Minor Allele Frequency (MAF) of the variation must be less than the frequency 
of the phenotype in the population. 
- M9: The inheritance pattern, penetrance and mechanism of the variant must be 
consistent with the disease. 
- M10: The studies provided by the bibliography must have at least 500 participants and is 
desirable that they are replicated. 
- M11: For pathogenic variants the Odds Ratio must me greater than 1, and for protective 
variants the Odds Ratio must be less than 1.  
- M12: For Genome Wide Association Studies (GWAS) the p-value must me less than 
5x10
-8
. 
Metrics M1, M2 and M3 help to identify errors that must be solved before the information is 
stored in the database and presented to the user. Metrics M4, M5, M8 and M9 help to identify 
conflict in the information provided from different repositories that could affect the Veracity of 
the information, for instance, different interpretations of pathogenicity for the same variation. 
The rest of metrics help to ensure that the information selected is sufficiently relevant for the 
task at hand. 
This strategy allowed us to identify 24 clinically relevant variations as the most meaningful 
ones. The process followed can be shown in Figure 7. Starting from the databases that store 
information about variations and diseases, the metrics were applied in a certain order to ensure 
the effectiveness of the process. Due to the same variation can be stored in different databases, it 
is important to identify duplicate entries before starting the identification. The issues associated 
to this task are explained in the next subsection. The RefSeq, NCBI Gene and dbSNP databases 
were used to complete the required information due to the nature of these repositories. As the 
identification process progresses, the number of variations is reduced. Finally, the variations 
from the original dataset are classified into 4 different categories: variations discarded due to 
contradictory evidence, variations discarded due to the lack of evidence associated to the disease, 
variations discarded due to not enough statistical relevance and variations accepted as relevant. 
This classification improves the traceability and replication of the results.  
It is important to notice that most of the variations were discarded due to the lack of relevant 
statistical evidence. This is caused by the characteristics of the disease. EOAD is a rare type of 
Alzheimer so the studies are performed over small populations or delimited families. Because of 
that, the evidence currently available is not enough to be used in clinical practice and more 
research needs to be done.  
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Figure 7. Flowchart of relevant data identification. The reduction in the number of variants is represented 
between brackets. The number of articles initially retrieved from PubMed is 1.264. 
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The information associated to the final set of variations is summarized in Table 6.  
Table 6. Relevant variants for Early Onset Alzheimer’s Disease ordered by number of associated 
publications. Ref. represents the original allele, Alt. represents the change which has occurred in the 
location of the chromosome specified by Chr (Position), and Num. Public. represents the number of 
publications associated to the variation. 
Variation ID Chr (Position) Ref. Alt. Num. Public Gene 
rs63751106 chr14 (73640351) T C 7 PSEN1 
rs63751416 chr14 (73683878) C G 7 PSEN1 
rs63750900 chr14 (73664775) G A 6 PSEN1 
rs63751024 chr14 (73659501) T C 6 PSEN1 
rs63749805 chr14 (73640285) C T 5 PSEN1 
rs63750323 chr14 (73683837) G C 5 PSEN1 
rs63751032 chr14 (73685864) T G 5 PSEN1 
rs63749835 chr14 (73659507) T C 4 PSEN1 
rs63750450 chr14 (73640279) A G 4 PSEN1 
rs63750730 chr14 (73640282) C T 4 PSEN1 
rs63749962 chr14 (73640278) T G 3 PSEN1 
rs63750004 chr14 (73640363) T C 3 PSEN1 
rs63750053 chr14 (73659429) G T 3 PSEN1 
rs63750569 chr14 (73659419) G A 3 PSEN1 
rs63750646 chr14 (73683855) G C 3 PSEN1 
rs63751399 chr14 (73637755) T C 3 PSEN1 
rs63750687 chr14 (73683845) C G 2 PSEN1 
rs63750779 chr14 (73664769) C T 2 PSEN1 
rs63750907 chr14 (73640375) C T 2 PSEN1 
rs63751003 chr14 (73659443) C T 2 PSEN1 
rs63751130 chr14 (73659506) C G 2 PSEN1 
rs63750298 chr14 (73673096) A C 1 PSEN1 
rs63750299 chr14 (73653598) T G 1 PSEN1 
rs63750863 chr14 (73664820) C T 1 PSEN1 
All of these variations affect processing or production of beta-amyloid, the protein fragment 
that is the main component of plaques in the brain. Plaques are abnormal clusters of protein 
fragments, build up between nerve cells.  Beta-amyloid is a prime suspect in decline and death of 
brain cells. Several drugs, currently under development, target beta-amyloid as a potential 
strategy to stop the disease or significantly slow its progression [29], [30]. This corroborates the 
importance and relevance of the selected variations. 
Once the relevant variations are determined, the next step is to identify which data must be 
extracted from each repository, in order to be stored in the HGDB. The information must be 
sufficient to allow the unambiguous identification of variations in a patient’s sample as well as 
provide enough data about their characteristics to support a genetic diagnosis. Each genomic 
repository provides different ways of accessing information as well as different data formats 
(VCF format, tabular text files, XML, etc.). 
Another problem is that due to the lack of standards to represent biological information, it is 
common to find different ways of representing the same concept. For instance, there are different 
ways to determine which nucleotides are affected by a variation: 
 dbSNP presents the nucleotides as two fields named “Ancestral Allele” and “RefSNP 
Alleles”. If the ancestral allele is an Adenine (A) and the RefSNP allele is a Guanine (G) this 
means that in a certain position of the DNA sequence, an A is changed by a G. 
 ClinVar uses the HGVS 15  Nomenclature to represent variations where a change of an 
Adenine and a Guanine are represented by a string such as NG_027670.1:g.292683A>G. 
                                               
15 HGVS Nomenclature: http://varnomen.hgvs.org/ 
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Even when both examples represent the same information and it is correct, data must be 
extracted using different approaches in order to ensure consistency. 
Once the information from each database is identified, the next step is to map it to the 
structure of the HGDB. Besides, the mechanisms to solve every possible inconsistency must be 
clearly defined in order to be implemented in the next level of SILE. 
6.3 Load 
Using an Extract-Transform-Load (ETL) process, the relevant data related with the variations 
identified in the previous level are loaded into the HGDB. By using the API provided by the 
selected data sources to access their content, a specific wrapper for each repository has been 
developed to extract the required data. 
In this level, the inconsistencies identified previously must be solved to be adequately stored 
in the database. This is the objective of the subsequent Transform process which ensures the 
Consistency of the system. The difficulty of the transformation process depends on the 
complexity of the field and its representation on each data source. 
One of the common problems to face when integrating the information from the selected 
databases is the recognition of duplicate entries. As can be seen in Figure 8, if we compare the 
original results of the databases that store information about genotype-phenotype relationships 
(variations) we can observe that 56 of them are common in all the repositories.  
 
Figure 8. Common variations in three of the selected genotype-phenotype databases 
Due to the lack of representation standards, the intersection of results force to verify if there 
are discrepancies in the information associated to each variation. For instance, it is common to 
find conflicts in the location of the variation in the genome. This happens because of the use of 
different reference sequences to locate the variations, which leads to discrepancies in the start 
and end positions. Ensembl uses the genome reference version GRCh38 (the latest one), ClinVar 
uses both and AlzForum uses the previous one (GRCh37). As a consequence, it is required to 
select one of the reference sequences and translate all values to the new coordinates. Another 
common error is related with the gene affected by the variation. Sometimes, the variation occurs 
in a sequence between two genes (intergenic) and the database shows the nearest gene to the 
variation. This leads to confusion because the variation is not located in that specific gene and 
maybe its function is not affected. It is important to take this situation into account because the 
knowledge evolves quickly and in the intergenic region a new gene can be found at any time. An 
example of this situation occurs when the variation is mapped according to old reference 
sequences.  
Another common source of errors is related with the reference and alternate alleles, that 
indicate the change which occurs in a certain position. The DNA is composed by two 
complementary chains, called forward strand and reverse strand. Depending on the strand, the 
alleles are different but not all the databases provide information about the strand used. This 
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information is the key to precisely identify a variation leading to an important problem of 
missing information when we try to identify the variations present in a patient’s sample. 
It is common to find inconsistencies in the nomenclature related with the type of variations, 
due to the lack of consensus in the use of standard terminology. For instance, Ensembl considers 
28 types of variations and ClinVar considers 31 types, based on type of change (insertion, 
deletion, etc.). Nevertheless, AlzForum classifies the variations according to their molecular 
consequence as well as the nucleotides changed (e.g. “Point, missense and GAC to CAC” is the 
type of the variation D678H). This situation requires to understand the ontology used by each 
data source in order to create a mapping among the different terms to guarantee the use of a 
unified terminology. A similar problem occurs with the name of the disease (phenotype) 
associated to the variation. There are different ontologies to classify traits and diseases such as 
the Human Phenotype Ontology [31], Human Disease Ontology [32] and MedGen
16
. In this case 
the mapping among terms is not a trivial task due to the complexity of the disease types and 
subtypes. 
All the problems previously mentioned hinder the process of finding duplicate entries and in a 
general way, the whole integration process. 
Once the errors have been corrected and the load has been finished the HGDB will store a set 
of variations selected according to the DQ established and ready to be analyzed by specific tools 
in order to extract the underlying knowledge. 
6.4 Exploitation 
The aim of the Exploitation level is to extract knowledge from the information system. 
Nevertheless, this is not a trivial task. Several tools have been developed to support the 
researchers in the genetic data analysis. However, the lack of intuitive and interactive-usable 
mechanisms of such tools converts the analysis activity into a complex and time-consuming task. 
In order to provide a solution useful for clinical purposes, the data exploitation tools must 
enhance data discovery, enlarge visualization, allow the performance of data analysis operations 
and contextualize data by augmenting it [33]. One of the tasks that can be performed is related 
with the enhancement of Precision Medicine (PM). As it has been explained in the introduction, 
PM is an emerging approach for disease treatment and prevention that takes into account 
individual variability in genes, environment, and lifestyle for each person. This approach allows 
doctors and researchers to predict more accurately which treatment and prevention strategies for 
a particular disease will work in which groups of people. It is in contrast to a one-size-fits-all 
approach, in which disease treatment and prevention strategies are developed for the average 
person, with less consideration for the differences between individuals.  
One of the pillars of PM is the genetic diagnosis which consists in the identification of 
potentially damaging variations in the DNA of a patient (see Figure 9).  
 
Figure 9. Architecture of a Genomic Information System (GeIS) for genetic diagnosis 
                                               
16 https://www.ncbi.nlm.nih.gov/medgen/ 
20 
 
Following this approach, a tool called VarSearch [34] has been developed, in order to point 
out genetic variations present on a patient’s sample. The information about the variations 
presented in the sample are stored in Variant Call Format
17
 (VCF) files, a standard widely 
accepted by the biological community. The VCF files are processed by VarSearch in order to 
determine which variations within the file are also among those stored in the HGDB. As a result, 
a personalized report is generated, indicating the risk of suffering the disease. 
In addition, VarSearch allows the researcher to go into detail on the characteristics of the 
variations found and the evidence that corroborates their relationship with the disease of interest. 
As all the information has been extracted from public repositories it confirms NCF being a 
valuable diagnosis tool for an advanced medicine of precision working environment. 
7 Conclusions and Future Work 
The interest on moving from a Big Data to a Smart Data perspective comes from the need to 
extract relevant data that can be used in daily work. This is especially important in fields such as 
genomics applied to clinical practice due to the increasing number of public resources that are 
becoming available, as well as their variable level of quality. 
In this article, we have established the importance of using Conceptual Models and Data 
Quality methodologies to define a roadmap to move from the Big Data perspective to the Smart 
Data perspective. The lack of an ontological commitment to define core biological terms is 
solved by using the CSHG. The variable level of quality, which affects the information available, 
is managed by the development of a Data Quality Methodology (DQM) based on specific 
dimensions and metrics. 
In order to make affordable the huge amount of available information, both solutions (CSHG 
and DQM) have been joined to develop a Genomic Information System (GeIS) with the aim of 
supporting the identification of clinically relevant variations in a patient’s sample. The 
consolidation has been made by defining SILE, a methodological approach whose main goal is 
to systematize the search and identification of genomic information to be loaded, analyzed and 
exploited by a GeIS. 
As a proof of concept, SILE has been applied under the context of searching relevant genes 
and variations related to the risk of suffering Early Onset Alzheimer’s Disease (EOAD). Due to 
the neuronal degeneration and the early appearance of its symptomatology, specific studies about 
its genetic characteristics are key to increase the quality of life of patients. SILE acts as a 
valuable tool that experts can use to manage the data which are relevant and sufficiently reliable 
for this task. A summary of the SILE method and the DQ dimensions used can be shown in 
Figure 10.  
The method has been successfully applied to identify the risk of suffering other diseases such 
as Neuroblastoma [35]. Currently, it is also being used to extend the underlying HGDB with 
information related to Crohn’s Disease, migraine, epilepsy and breast cancer. Moreover, a 
project in collaboration with clinical experts in lung cancer from the “Hospital de Clínicas” in 
Asuncion Paraguay is under a promising development. 
Genomics research is under constant evolution and data are generated quicker and quicker. 
The perspective of Big Data to Smart Data requires that our strategy must be able to adapt to any 
changes and new findings. The refinement of the tasks to perform at each level of SILE, the 
evolution of the CSHG and the quality controls that are applied form a cyclic process that must 
be continuously refined. This ensures the fulfillment of the knowledge needs as long as the 
evolution of the domain continues. 
                                               
17 http://www.internationalgenome.org/wiki/Analysis/vcf4.0/ 
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Figure 10. The SILE Method 
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